Avalo Therapeutics Inc: 5%+ holders

As of November 10, 2026, 11 holders' latest Schedule 13D or 13G filings report owning 5% or more of Avalo Therapeutics Inc. The largest reported stake is Commodore Capital LP's, at 9.9%. 59 filings are on record since August 5, 2025 (Schedule 13G, June 18, 2026).

Patrick J. Crutcher also filed stake reports on 1 other company ↓

Sell to companies like Avalo Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-11-06 · Holder: Fmr LLC · Percent: 0.9% · SCHEDULE 13G/A
• Filed 2026-11-05 · Holder: Fmr LLC · Percent: 9.8% · SCHEDULE 13G/A
• Filed 2026-10-29 · Holder: Trails Edge Capital Partners, LP · Percent: 5.2% · SCHEDULE 13G
• Filing 2026-08-14 · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 3,610,000 · Sole dispositive: 0 · Shared dispositive: 3,610,000 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 3,483,099 · Sole dispositive: 0 · Shared dispositive: 3,483,099 · SCHEDULE 13G/A, 2026-08-14

Avalo Therapeutics Inc has 59 Schedule 13D or 13G filings on record since 2025-08-05. 11 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Avalo Therapeutics Inc and the warning signs.

See Avalo Therapeutics Inc's free Snapshot Watch Avalo Therapeutics Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Avalo Therapeutics Inc and the records around it.

Avalo Therapeutics Inc elsewhere on the record

• Leadership changes Jun 2026
• Who owns it

Companies that share a holder

• Patrick J. Crutcher also filed stake reports on 1 other company: IBIO, INC. (Jul 2025)
• SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
• Caligan Partners LP also filed stake reports on 9 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Opus Genetics, Inc. (Aug 2026)

Want the whole picture on Avalo Therapeutics Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Avalo Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Avalo Therapeutics Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   61 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Avalo Therapeutics Inc by CUSIP 05338F306 and gives its principal executive office as 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA 19087 (SCHEDULE 13G/A, 2026-11-06).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14

As of June 30, 2026, the Reporting Persons beneficially own approximately 5.5% of the Common Stock outstanding. The percentages disclosed above are based on 52,900,692 shares of Common Stock of the Issuer outstanding as of June 30, 2026, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026.Affinity Asset Advisors, LLC, SCHEDULE 13G/A, 2026-08-13

The following percentages are based upon a denominator that is the sum of (i) 52,565,572 Shares outstanding as of May 8, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2026 and (ii) 726,000 Shares issuable upon the conversion of the Series C Preferred Stock owned by the Reporting Persons, as applicable.Bvf Partners L P, SCHEDULE 13G/A, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Avalo Therapeutics Inc

Who owns Avalo Therapeutics Inc?

On this page, 11 holders' latest ownership filings report 5% or more of Avalo Therapeutics Inc: Commodore Capital LP (9.9%, Schedule 13G, filed 2026-06-18), TCG Crossover GP II, LLC (7.9%, Schedule 13G, filed 2026-05-12), Deep Track Capital, LP (6.87%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (6.5%, Schedule 13G, filed 2026-07-27) and RA Capital Management, L.P. (6.3%, Schedule 13G/A, filed 2026-08-14); 6 more are listed above.

Who are the largest shareholders of Avalo Therapeutics Inc?

By the share each holder's latest filing reports, the largest holders of Avalo Therapeutics Inc on this page are Commodore Capital LP (9.9%), TCG Crossover GP II, LLC (7.9%) and Deep Track Capital, LP (6.87%).

When did Commodore Capital LP buy into Avalo Therapeutics Inc?

The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G, filed 2026-06-18, reporting 9.9%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 59 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Avalo Therapeutics Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Avalo Therapeutics Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Avalo Therapeutics Inc is mentioned again
• Find former Avalo Therapeutics Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes